Key Insights

Highlights

Success Rate

72% trial completion

Published Results

119 trials with published results (11%)

Research Maturity

354 completed trials (34% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

13.0%

137 terminated out of 1054 trials

Success Rate

72.1%

-14.4% vs benchmark

Late-Stage Pipeline

1%

11 trials in Phase 3/4

Results Transparency

34%

119 of 354 completed with results

Key Signals

119 with results72% success137 terminated

Data Visualizations

Phase Distribution

962Total
Not Applicable (64)
Early P 1 (41)
P 1 (744)
P 2 (102)
P 3 (4)
P 4 (7)

Trial Status

Completed354
Recruiting274
Unknown142
Terminated137
Active Not Recruiting72
Not Yet Recruiting41

Trial Success Rate

72.1%

Benchmark: 86.5%

Based on 354 completed trials

Clinical Trials (1054)

Showing 20 of 20 trials
NCT05382559Phase 1RecruitingPrimary

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT07489378Recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

NCT07739966Phase 1Not Yet RecruitingPrimary

A Study of DS-3939a in Participants With Solid Tumors

NCT06305247Phase 1Active Not Recruiting

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT05245136Recruiting

Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool.

NCT06160752Phase 1Recruiting

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

NCT05037149Phase 1CompletedPrimary

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

NCT07374419Phase 1Recruiting

Atamparib in Patients With Advanced Solid Tumors

NCT04198766Phase 1RecruitingPrimary

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT07676903Phase 1Not Yet RecruitingPrimary

A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors

NCT05907980Phase 1RecruitingPrimary

A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

NCT06619587Phase 1RecruitingPrimary

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT05840224Phase 1Active Not RecruitingPrimary

Study of GS-4528 in Adults With Solid Tumors

NCT05826600Phase 1TerminatedPrimary

A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically

NCT04939610Phase 1RecruitingPrimary

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

NCT06475300Phase 2Recruiting

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

NCT06008483Phase 1Terminated

A Dose Finding Study to Treat Bone Tumor(s)

NCT05919264Phase 1Recruiting

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT07589205Phase 1RecruitingPrimary

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

NCT06234098Phase 1RecruitingPrimary

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

Scroll to load more

Research Network

Activity Timeline